Filtered By:
Condition: Headache
Education: Learning

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 92 results found since Jan 2013.

Automatic Classification of the Korean Triage Acuity Scale in Simulated Emergency Rooms Using Speech Recognition and Natural Language Processing: a Proof of Concept Study
CONCLUSION: We demonstrated the potential of an automatic KTAS classification system using speech recognition models, machine learning and BERT-based classifiers.PMID:34254471 | DOI:10.3346/jkms.2021.36.e175
Source: J Korean Med Sci - July 13, 2021 Category: General Medicine Authors: Dongkyun Kim Jaehoon Oh Heeju Im Myeongseong Yoon Jiwoo Park Joohyun Lee Source Type: research

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Concussions and kids: Project co-led by UCLA gets $10 million grant from NIH
A research project co-led by theUCLA Steve Tisch BrainSPORT Programaimed at improving the assessment and treatment of concussions in school-aged children has been awarded $10 million by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health.The grant to the Four Corners Youth Consortium, agroup of academic medical centers studying pediatric concussions, will supportConcussion Assessment, Research and Education for Kids, or CARE4Kids, a multisite study that will enroll more than 1,300 children and teens nationwide, including an estimated 240 in Southern California.CARE4Kids re...
Source: UCLA Newsroom: Health Sciences - October 7, 2021 Category: Universities & Medical Training Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

IJERPH, Vol. 19, Pages 4014: Automated Detection of Hypertension Using Continuous Wavelet Transform and a Deep Neural Network with Ballistocardiography Signals
Acharya Managing hypertension (HPT) remains a significant challenge for humanity. Despite advancements in blood pressure (BP)-measuring systems and the accessibility of effective and safe anti-hypertensive medicines, HPT is a major public health concern. Headaches, dizziness and fainting are common symptoms of HPT. In HPT patients, normalcy may be observed at one instant and abnormality may prevail during a long duration of 24 h ambulatory BP. This may cause difficulty in identifying patients with HPT, and hence there is a possibility that individuals may be untreated or administered insufficiently. Most importantly, u...
Source: International Journal of Environmental Research and Public Health - March 28, 2022 Category: Environmental Health Authors: Jaypal Singh Rajput Manish Sharma T. Sudheer Kumar and U. Rajendra Acharya Tags: Article Source Type: research

What Causes Sudden Vision Loss?
Discussion Vision loss, whether chronic or acute, is distressing at any time for patients and families. Prompt evaluation and treatment are important as maintenance of any acuity and light or movement is considered paramount. Most vision loss is due to chronic problems and aging issues but the differential diagnosis is broad. For any age, but especially children, uncorrected refractive errors can cause problems in not only in childhood but throughout someone’s lifetime. Visual impairment for distance vision is considered mild if worse than 6/12 in meters = 20/40 in feet or 0.3 LogMAR and for moderate impairment is 6/...
Source: PediatricEducation.org - September 5, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Neurological Effects of Monkeypox Largely Unknown, Review Finds
Much remains unknown about the long-term neurologic effects of monkeypox. In anarticle published today inJAMA Neurology, researchers from the National Institute of Neurological Disorders and Stroke (NINDS) and colleagues described how reports of complications from other orthopoxviruses, such as smallpox, may offer clues about the neurologic consequences of monkeypox.“Although the COVID-19 pandemic is the worst pandemic in a century, the recent past has seen several major pandemics, including Zika, Ebola, dengue, West Nile, and AIDS,” wrote B. Jeanne Billioux, M.D., of NINDS and colleagues. “A common thread to these p...
Source: Psychiatr News - September 20, 2022 Category: Psychiatry Tags: febrile seizures/encephalopathy headache JAMA Neurology monkeypox neurological problems smallpox transverse myelitis Source Type: research

Cerebral blood flow alterations in migraine patients with and without aura: An arterial spin labeling study
ConclusionIn this study, CBF abnormalities of MwA were identified in multiple brain regions, which might help better understand migraine-stroke connection mechanisms and may guide patient-specific decision-making.
Source: The Journal of Headache and Pain - October 4, 2022 Category: Neurology Source Type: research